Biogen tops profit estimates as cost cuts take hold, Alzheimer’s drug Leqembi launch picks up

A test tube is seen in front of displayed Biogen logo in this illustration taken on,…

Sage Therapeutics stock plunges more than 50% after FDA denies wider use of postpartum depression drug

In this photo illustration, the Sage Therapeutics logo of a biopharmaceutical company seen on a smartphone…

These health-care companies see opportunity ahead from Alzheimer’s drug approval

As patients with Alzheimer’s disease seek out a newly approved treatment, they will need MRIs, blood…

Medicare will pay for Alzheimer’s drug Leqembi. What patients and doctors should know

The Alzheimer’s drug Leqembi is seen in this undated handout image obtained by Reuters on January…

FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverage

The Food and Drug Administration on Thursday fully approved the Alzheimer’s treatment Leqembi, a pivotal decision…

Sales of Alzheimer’s drug Leqembi may be slow initially but could pick up in 2024

Jay Reinstein, who suffers from Alzheimer’s, receives an injection so he can have a PET scan…

Newseum Global